Algorae Pharmaceuticals Limited (LVCLY)
- Previous Close
0.0246 - Open
0.0465 - Bid 0.0306 x --
- Ask 0.0640 x --
- Day's Range
0.0246 - 0.0299 - 52 Week Range
0.0200 - 0.0800 - Volume
1,580 - Avg. Volume
2,338 - Market Cap (intraday)
6.367M - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Aug 28, 2024 - Sep 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Algorae Pharmaceuticals Limited, a biotechnology company, focuses on developing solutions for Parkinson's disease in Australia. It is developing NTCELL, an alginate coated capsule to target the treatment of Parkinson's disease; and AI-116, a novel combination drug candidate, which includes cannabidiol and an off-patent pharmaceutical ingredient treatment for dementia, including Alzheimer's disease. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. The company was founded in 1987 and is based in Melbourne, Australia.
www.algoraepharma.comRecent News: LVCLY
Performance Overview: LVCLY
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LVCLY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LVCLY
Valuation Measures
Market Cap
12.94M
Enterprise Value
10.53M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.50
Enterprise Value/Revenue
2.68k
Enterprise Value/EBITDA
-3.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.02%
Return on Equity (ttm)
-70.91%
Revenue (ttm)
42.02k
Net Income Avi to Common (ttm)
-2.25M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.62M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-540.25k
Company Insights: LVCLY
LVCLY does not have Company Insights